Last updated: May 29, 2026
Executive summary: Bupivacaine hydrochloride (local anesthetic) is supplied globally by a mix of brand-formulation manufacturers (injectables), generic sterile manufacturers (including ampoule/vial formats), and contract manufacturers that produce sterile liquids and lyophilized variants. At the API and intermediate level, supply is concentrated among large-scale generics/API specialists and diversified fine-chemical producers, while finished-dose sterile products are produced by a broader set of sterile CMO/CDMO networks. Commercially, the supplier landscape is driven by (1) U.S. FDA sterile manufacturing capability, (2) compliance with aseptic and container-closure requirements for injectable anesthetics, and (3) whether the product is supplied as bupivacaine HCl plain drug, with specific salt forms, concentration, and container (vial vs ampoule) matching approved labeling.
No supplier list is provided below because the minimum required source-backed data (specific named suppliers by product strength/form, FDA label references, and/or Orange Book API/finished-dose manufacturer links) is not available in the input. Under the operating constraints, producing an incomplete or non-verifiable supplier roster would violate the requirement for completeness and accuracy.
Which companies supply bupivacaine hydrochloride (Bupivacaine HCl) finished-dose injectables in the US?
Featured snippet answer: Identify suppliers by tracing the NDA/ANDA references for each strength and dosage form (vials/ampoules) and then mapping manufacturers to their FDA label “Manufactured for” and/or applicant/holder entities. Supplier names change by strength and marketing authorization.
Dosage forms that determine supplier lists
- Injectable solutions (typical for surgical and regional anesthesia)
- Concentration variants (for example, 0.25% to 0.75% classed strengths)
- Container formats (vial vs ampoule)
- Preservative status and excipient sets (which affect which sterile suppliers can qualify)
- Device associations (where applicable)
H3: How do Orange Book and FDA label manufacturing sections affect supplier identification?
- Orange Book lists are tied to approved drug product applications; they identify the applicant/holder and, indirectly, where the marketed product is sourced.
- FDA labels typically name the “Manufactured for” entity, which is often not the same as the underlying sterile fill-finish CMO.
- Litigation and transfer of ANDA ownership can alter supplier appearance even when manufacturing continues through the same underlying CDMO.
Who supplies bupivacaine hydrochloride API (active pharmaceutical ingredient) globally?
Featured snippet answer: API supply is typically provided by API-focused manufacturers and large fine-chemical producers that can support chiral synthesis, quality systems, and regulatory documentation aligned to injectable-grade requirements.
H3: What manufacturing capabilities gate API supply for injectable local anesthetics?
- Consistent chiral purity and impurities profile management
- Injectable-grade specifications (residual solvents, water content where relevant)
- Batch traceability and stability program alignment
- Sterility is not applicable to API, but microbiological and endotoxin controls can be relevant for downstream aseptic lots
How many suppliers cover bupivacaine HCl sterile injectables and what is the supplier concentration?
Featured snippet answer: The number of suppliers varies by strength, concentration, and approved labeling. Finished-dose coverage is broader than API coverage due to sterile fill-finish and packaging ecosystems.
H3: What drives supplier concentration
- Limited sterile injectable capacity for certain vial/ampoule configurations
- Qualification timelines for hospitals and procurement contracts
- Regulatory inspection history and data integrity remediation impacts
- Supply chain switching costs for container-closure systems and stoppering/closure validation
Which contract manufacturing organizations (CMOs/CDMOs) make bupivacaine hydrochloride sterile vials or ampoules?
Featured snippet answer: CDMO/CMO identification requires mapping labeled manufacturers to underlying fill-finish vendors, which is usually not disclosed publicly for every product.
H3: How to interpret CMO involvement in bupivacaine products
- The FDA label’s “Manufactured for” entity is frequently the ANDA holder
- The sterile manufacturing and filling step can be performed by a third party without being named as the primary label manufacturer
- Changes in CMO networks can occur through supplement filings without changing the applicant name
What bupivacaine hydrochloride formulations exist and how does that change supplier sourcing?
Featured snippet answer: Supplier lists vary by the precise formulation characteristics: concentration, container type, excipients, preservative system, and whether the product is intended for specific anesthesia use-cases.
H3: Key formulation variables
- Strength (percentage w/v)
- Presence/absence of preservative system
- Buffering system and pH range
- Compatibility with sterilization and storage temperature profiles
- Packaging configuration (single-dose vial vs ampoule)
What is the regulatory status (FDA, Orange Book) of bupivacaine hydrochloride products that drive supplier eligibility?
Featured snippet answer: Regulatory status is determined product-by-product through FDA’s drug approval database (NDA/ANDA) and the Orange Book for listed patents (if any). Supplier eligibility tracks the specific approved application tied to each marketed strength.
H3: Why exclusivity and listed patents are not the main filter for generic supply
- For widely genericized local anesthetics, most supplier constraints are manufacturing and quality-system driven rather than patent driven
- Still, application ownership can shift due to patent settlements and 505(b)(2)/ANDA litigation outcomes
What generic entry risks exist for new bupivacaine hydrochloride suppliers?
Featured snippet answer: The main risks are sterile manufacturing qualification and regulatory inspection outcomes rather than formulation novelty.
H3: Operational entry barriers
- Aseptic process validation and media fill success
- Closure integrity and container-closure compatibility
- Stability and shipping qualification for the labeled container format
- Supply continuity (raw material sourcing and hold-time validation)
How do bupivacaine hydrochloride supplier choices compare with alternatives like lidocaine or ropivacaine?
Featured snippet answer: Alternatives have similar sterile-injectable bottlenecks, but the exact supplier set differs due to:
- API synthesis route and chiral or impurity control requirements
- Strength-specific labeling and excipient systems
- Different procurement formularies by hospital systems
H3: What changes in procurement dynamics
- Therapeutic substitution policies
- Pharmacy contracting preferences
- Allergy and local anesthetic class cross-application rules
Key Takeaways
- Bupivacaine hydrochloride supplier identification is product- and strength-specific and is best derived from FDA-labeled “manufactured for” entities tied to approved NDAs/ANDAs.
- API supply is more concentrated than finished-dose sterile supply due to specialized chemical and quality requirements.
- Finished-dose supplier availability depends heavily on sterile fill-finish capacity, container-closure qualification, and inspection readiness.
FAQs
- How can I identify the manufacturer of a specific bupivacaine hydrochloride strength in the US supply chain?
- Do bupivacaine hydrochloride ampoules and vials come from the same manufacturing suppliers?
- What evidence in FDA documentation links a finished-dose bupivacaine product to its underlying sterile fill-finish site?
- Are there different suppliers for bupivacaine HCl based on preservative systems or excipients?
- What are the most common regulatory or quality-system reasons sterile injectable suppliers lose supply continuity?
References
(No sources were provided in the input, and no verifiable supplier list can be produced without citations.)
